Interestingly, when compared to placebo group, the proportion of Th17 cells and the expression level of RORγt and IL-17 were significantly decreased in MS patients who received weekly interferon β-1a (Actovex) injections and supplemented with NanoCUR for 6 months [113]. The gene discussed is IL17A; the disease is myeloid sarcoma.